BRIEF—Enlivex raises $5.4 million along with completing Bioblast merger

Israeli immunotherapy company Enlivex Therapeutics has raised nearly $5.4 million in a private offering, along with the completion of its merger with Bioblast Pharma.

The financing was led by existing investors KIP Global Pharma Private Equity Fund, an affiliate of Seoul-headquartered venture firm Korea Investment Partners and Jerusalem-based biotech Hadasit Bio Holdings.

Since last September, Enlivex has now raised $10.6 million. This cash will allow initiation of several late-stage immunotherapy clinical trials.